scholarly journals Reply to Chemical Risk Factors of Primary Liver Cancer: A Short Comment [Response To Letter]

2021 ◽  
Vol Volume 13 ◽  
pp. 145-146
Author(s):  
Adam Barsouk ◽  
Krishna Chaitanya Thandra ◽  
Kalyan Saginala ◽  
Prashanth Rawla
2021 ◽  
Vol Volume 12 ◽  
pp. 179-188
Author(s):  
Adam Barsouk ◽  
Krishna Chaitanya Thandra ◽  
Kalyan Saginala ◽  
Prashanth Rawla ◽  
Alexander Barsouk

Author(s):  
Tu Ji-Tao ◽  
Gao Ru-Nie ◽  
Zhang Dan-Hua ◽  
Gu Bin-Chang ◽  
Xu Guan-Xiong ◽  
...  

2020 ◽  
Vol 44 (9) ◽  
pp. 3093-3099 ◽  
Author(s):  
Akira Mori ◽  
Akira Arimoto ◽  
Yuhei Hamaguchi ◽  
Masatoshi Kajiwara ◽  
Akio Nakajima ◽  
...  

Author(s):  
Javier Salazar ◽  
Anne Le

AbstractPrimary liver cancer is the fourth leading cause of cancer death around the world. Histologically, it can be divided into two major groups, hepatocellular carcinoma (75% of all liver cancer) and intrahepatic cholangiocarcinoma (15% of all liver cancer) [1, 2]. Primary liver cancer usually happens in liver disease or cirrhosis patients [1], and the risk factors for developing HCC depend on the etiology [3] and the country of provenance [1]. There is an urgent need for an accurate diagnostic test given the high proportion of false positives and false negatives for alpha-fetoprotein (AFP), a common HCC biomarker [4]. Due to often being diagnosed in advanced stages, HCCrelated deaths per year have doubled since 1999 [3]. With the use of metabolomics technologies [5], the aberrant metabolism characteristics of cancer tissues can be discovered and exploited for the new biomarkers and new therapies to treat HCC [6, 7].


2011 ◽  
Vol 131 (1) ◽  
pp. 193-200 ◽  
Author(s):  
Wegene Borena ◽  
Susanne Strohmaier ◽  
Annekatrin Lukanova ◽  
Tone Bjørge ◽  
Björn Lindkvist ◽  
...  

Epidemiology ◽  
1995 ◽  
Vol 6 (1) ◽  
pp. 36-41 ◽  
Author(s):  
Marc T. Goodman ◽  
Hiroko Moriwaki ◽  
Michael Vaeth ◽  
Suminori Akiba ◽  
Hitomi Hayabuchi ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document